The randomized clinical trial — conducted by researchers from the U.S., Israel, Canada and the Netherlands — involved 2,221 people and compared the ridaforolimus-eluting stent from Medinol with the zotarolimus-eluting stent from Medtronic.
After two years, the one-year target lesion failure was 7.0% for the EluNIR stent versus 7.2% for the Medtronic stents. Rates of target lesion revascularization were 4.8% for EluNIR versus 4.1% for Resolute, and target vessel-related myocardial infarction was 3.1% for EluNIR versus 3.8% for Resolute. The overall rate of stent thrombosis was also similar between the stents, 3.1% for EluNIR and 3.8% for Resolute.
The researchers are publishing their results in the Jan. 13 edition of The American College of Cardiology Foundation’s JACC: Cardiovascular Interventions journal. The research group included a doctor who is an employee of Medinol, and another doctor in the group has served on the companies medical advisory board and owns equity in the company.
Approved by FDA in 2017, the first commercial implants of EluNIR took place in the U.S. in early 2018. The Cordis business at Cardinal Health (NYSE:CAH) is the stent’s U.S. distributor.
Medinol says it designed the EluNIR stent for easily delivery in complex anatomy and disease — with a novel metallic spring tip. The company has boasted that EluNIR has the narrowest strut width of any stent on the U.S. market.
